FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315703045> ?p ?o ?g. }

• W4315703045 endingPage "e25" @default.
• W4315703045 startingPage "e25" @default.
• W4315703045 abstract "Objective: Altered adipokine secretion in dysfunctional adipose tissue facilitates the development of atherosclerotic diseases including lower extremity peripheral artery disease (PAD). Asprosin is a recently identified adipokine and displays potent regulatory role in metabolism, but the relationship between asprosin and lower extremity PAD remains uninvestigated. In this study, we investigated the effect of asprosin accounting for the lower extremity vascular injury in diabetic patients based on the metabolic profiles of PAD. Design and method: 33 type 2 diabetes mellitus (T2DM) patients (DM), 51 T2DM patients with PAD (DM+PAD) and 30 healthy normal control (NC) volunteers were recruited and the blood samples were collected for detecting the circulatory asprosin level and metabolomic screening. RNA sequencing was performed using the aorta tissues from the type 2 diabetic db/db mice and its control db/m mice. Moreover, human umbilical vein endothelial cells (HUVECs) were treated with asprosin to determine its impact on the endothelial-to-mesenchymal transition (EndMT). Results: The circulating levels of asprosin in DM+PAD group were significantly higher than that of NC group and the DM group. Circulating asprosin level was remarkably negatively correlated with ankle-brachial index (ABI), even after adjusting for age, sex, body mass index (BMI) and other traditional risk factors of PAD (P = 0.049). Logistic regression analysis revealed that asprosin is an independent risk factor for PAD (OR:3.944, 95%CI:1.656 − 9.393, P = 0.002) and receiver-operator characteristic (ROC) curve determined a cut-off value at 188.70 ng/ml with a good sensitivity (74.5%) and specificity (74.6%) of asprosin to distinguish PAD (Area under curve:0.788, 95%CI:0.694 − 0.863, P < 0.001). Data from metabolomics displayed a typical characteristics of de novo amino acid synthesis in collagen protein production by myofibroblasts in which TGF-beta signaling pathway might plays a critical role in patients with PAD. In addition, activation of TGF-beta signaling pathway also appeared in the aortic tissue of db/db mice, suggesting a causal relationship between TGF-beta signaling pathway and artery injury. Asprosin directly induces EndMT in HUVECs in a TGF-beta-dependent manner as TGF-beta signaling pathway inhibitor SB431542 erased the promotional effect of asprosin on EndMT. Conclusions: Elevated circulatory asprosin level is an independent risk factor of lower extremity PAD and might serve as a diagnostic marker. Mechanistically, asprosin directly induces EndMT that participates in vascular injury via activation of TGF-beta signaling pathway." @default.
• W4315703045 created "2023-01-12" @default.
• W4315703045 creator A5005394149 @default.
• W4315703045 creator A5010985917 @default.
• W4315703045 creator A5018552483 @default.
• W4315703045 creator A5058659834 @default.
• W4315703045 date "2023-01-01" @default.
• W4315703045 modified "2023-10-02" @default.
• W4315703045 title "S-07-5: ASPROSIN INDUCES VASCULAR ENDOTHELIAL- TO-MESENCHYMAL TRANSITION IN DIABETIC LOWER EXTREMITY PERIPHERAL ARTERY DISEASE" @default.
• W4315703045 doi "https://doi.org/10.1097/01.hjh.0000912944.72016.15" @default.
• W4315703045 hasPublicationYear "2023" @default.
• W4315703045 type Work @default.
• W4315703045 citedByCount "0" @default.
• W4315703045 crossrefType "journal-article" @default.
• W4315703045 hasAuthorship W4315703045A5005394149 @default.
• W4315703045 hasAuthorship W4315703045A5010985917 @default.
• W4315703045 hasAuthorship W4315703045A5018552483 @default.
• W4315703045 hasAuthorship W4315703045A5058659834 @default.
• W4315703045 hasBestOaLocation W43157030451 @default.
• W4315703045 hasConcept C126322002 @default.
• W4315703045 hasConcept C134018914 @default.
• W4315703045 hasConcept C164705383 @default.
• W4315703045 hasConcept C171089720 @default.
• W4315703045 hasConcept C194832188 @default.
• W4315703045 hasConcept C2777391703 @default.
• W4315703045 hasConcept C2780221984 @default.
• W4315703045 hasConcept C2780972559 @default.
• W4315703045 hasConcept C2910068830 @default.
• W4315703045 hasConcept C46762472 @default.
• W4315703045 hasConcept C555293320 @default.
• W4315703045 hasConcept C71924100 @default.
• W4315703045 hasConceptScore W4315703045C126322002 @default.
• W4315703045 hasConceptScore W4315703045C134018914 @default.
• W4315703045 hasConceptScore W4315703045C164705383 @default.
• W4315703045 hasConceptScore W4315703045C171089720 @default.
• W4315703045 hasConceptScore W4315703045C194832188 @default.
• W4315703045 hasConceptScore W4315703045C2777391703 @default.
• W4315703045 hasConceptScore W4315703045C2780221984 @default.
• W4315703045 hasConceptScore W4315703045C2780972559 @default.
• W4315703045 hasConceptScore W4315703045C2910068830 @default.
• W4315703045 hasConceptScore W4315703045C46762472 @default.
• W4315703045 hasConceptScore W4315703045C555293320 @default.
• W4315703045 hasConceptScore W4315703045C71924100 @default.
• W4315703045 hasIssue "Suppl 1" @default.
• W4315703045 hasLocation W43157030451 @default.
• W4315703045 hasLocation W43157030452 @default.
• W4315703045 hasOpenAccess W4315703045 @default.
• W4315703045 hasPrimaryLocation W43157030451 @default.
• W4315703045 hasRelatedWork W1782957512 @default.
• W4315703045 hasRelatedWork W1964688190 @default.
• W4315703045 hasRelatedWork W2017606817 @default.
• W4315703045 hasRelatedWork W2027098794 @default.
• W4315703045 hasRelatedWork W2049045125 @default.
• W4315703045 hasRelatedWork W2081564223 @default.
• W4315703045 hasRelatedWork W2086591008 @default.
• W4315703045 hasRelatedWork W2167541966 @default.
• W4315703045 hasRelatedWork W2516942758 @default.
• W4315703045 hasRelatedWork W2547949331 @default.
• W4315703045 hasVolume "41" @default.
• W4315703045 isParatext "false" @default.
• W4315703045 isRetracted "false" @default.
• W4315703045 workType "article" @default.